Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2018-11-13 Earnings Release
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
8-K Q3 2018 EARNING RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 13, 2018, reporting the financial results for the quarter ended September 30, 2018. It specifically mentions that the full text of the press release announcing the quarterly financial results is furnished as an exhibit. The document is short (3897 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim report or annual report.
2018-11-13 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-09 English
FORM 4 SUBMISSION
Director's Dealing
2018-09-14 English
FORM 4 SUBMISSION
Director's Dealing
2018-09-08 English
RW
Regulatory Filings Classification · 100% confidence The document is a letter from Novus Therapeutics, Inc. to the SEC requesting withdrawal of a Registration Statement on Form S-1. It references regulatory rules under the Securities Act of 1933 and discusses the withdrawal of a registration statement related to a public offering that was not declared effective. The document is short (1977 characters) and is a formal regulatory communication rather than a financial report or announcement of results. It does not contain financial data, earnings, or management discussion. It is a regulatory filing related to the withdrawal of a registration statement, which fits best under the category of Regulatory Filings (RNS).
2018-09-07 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, dated September 4, 2018. It is a registration statement under the Securities Act of 1933 for Novus Therapeutics, Inc. The text includes detailed information about the company, the securities offering (6,000,000 shares of common stock), risk factors, use of proceeds, capitalization, dilution, description of capital stock, underwriting, legal matters, and other typical content of a registration statement prospectus. The document is not a financial report like an annual or quarterly report, nor is it an earnings release or a call transcript. It is a regulatory filing related to the company's initial public offering or securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains the full text of the registration statement amendment, not just an announcement or a certification, supporting a high confidence in this classification.
2018-09-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.